Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in patients with metastatic uveal melanoma

Jade Homsi, Agop Y. Bedikian, Nicholas E. Papadopoulos, Kevin B. Kim, Wen Jen Hwu, Sandy L. Mahoney, Patrick Hwu

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Docosahexaenoic acid (DHA)-paclitaxel is a taxane with a unique pharmacokinetic profile. We investigated the safety and response rate of DHA-paclitaxel weekly in patients with metastatic uveal melanoma. Chemotherapy-naive and previously treated patients were eligible for this open-label phase II study. DHA-paclitaxel (500mg/m/week) was administered by a 1-hour intravenous infusion for five consecutive weeks in a 6-weeks cycle. Response was assessed using the Response Evaluation Criteria in Solid Tumors every 6 weeks. Twenty-two patients were enrolled. The patients' median age was 56 years (range: 33-79 years). Nine patients had a systemic therapy for metastatic disease earlier. The median number of treatment cycles was 1 (range 1-7 cycles). One chemonaive patient with liver metastases had partial response lasting for 5 months. Seven patients (32%) had stable disease with a median duration of 3 months (range: 3-7 months). The median overall survival was 9.8 months. Neutropenia (23%) and musculoskeletal pain (10%) were the most common grade 3 and grade 4 toxicities. As a single-agent therapy, DHA-paclitaxel is safe and well-tolerated in metastatic uveal melanoma patients. Its efficacy in this disease is limited with 32% of patients achieving stable disease. Further evaluation of DHA-paclitaxel in combination with other chemotherapeutic agents and/or targeted agents may improve its antitumor activity.

Original languageEnglish (US)
Pages (from-to)507-510
Number of pages4
JournalMelanoma Research
Volume20
Issue number6
DOIs
StatePublished - Dec 1 2010

Fingerprint

docosahexaenoyl-paclitaxel
Uveal melanoma
Musculoskeletal Pain
Neutropenia
Intravenous Infusions
Therapeutics
Pharmacokinetics
Neoplasm Metastasis
Safety
Drug Therapy
Survival
Liver
Response Evaluation Criteria in Solid Tumors
taxane

Keywords

  • chemotherapy
  • melanoma
  • paclitaxel
  • uveal

ASJC Scopus subject areas

  • Oncology
  • Dermatology
  • Cancer Research

Cite this

Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in patients with metastatic uveal melanoma. / Homsi, Jade; Bedikian, Agop Y.; Papadopoulos, Nicholas E.; Kim, Kevin B.; Hwu, Wen Jen; Mahoney, Sandy L.; Hwu, Patrick.

In: Melanoma Research, Vol. 20, No. 6, 01.12.2010, p. 507-510.

Research output: Contribution to journalArticle

Homsi, Jade ; Bedikian, Agop Y. ; Papadopoulos, Nicholas E. ; Kim, Kevin B. ; Hwu, Wen Jen ; Mahoney, Sandy L. ; Hwu, Patrick. / Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in patients with metastatic uveal melanoma. In: Melanoma Research. 2010 ; Vol. 20, No. 6. pp. 507-510.
@article{dc3a3b05c7c74754ab7bffaa9f5f3a9a,
title = "Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in patients with metastatic uveal melanoma",
abstract = "Docosahexaenoic acid (DHA)-paclitaxel is a taxane with a unique pharmacokinetic profile. We investigated the safety and response rate of DHA-paclitaxel weekly in patients with metastatic uveal melanoma. Chemotherapy-naive and previously treated patients were eligible for this open-label phase II study. DHA-paclitaxel (500mg/m/week) was administered by a 1-hour intravenous infusion for five consecutive weeks in a 6-weeks cycle. Response was assessed using the Response Evaluation Criteria in Solid Tumors every 6 weeks. Twenty-two patients were enrolled. The patients' median age was 56 years (range: 33-79 years). Nine patients had a systemic therapy for metastatic disease earlier. The median number of treatment cycles was 1 (range 1-7 cycles). One chemonaive patient with liver metastases had partial response lasting for 5 months. Seven patients (32{\%}) had stable disease with a median duration of 3 months (range: 3-7 months). The median overall survival was 9.8 months. Neutropenia (23{\%}) and musculoskeletal pain (10{\%}) were the most common grade 3 and grade 4 toxicities. As a single-agent therapy, DHA-paclitaxel is safe and well-tolerated in metastatic uveal melanoma patients. Its efficacy in this disease is limited with 32{\%} of patients achieving stable disease. Further evaluation of DHA-paclitaxel in combination with other chemotherapeutic agents and/or targeted agents may improve its antitumor activity.",
keywords = "chemotherapy, melanoma, paclitaxel, uveal",
author = "Jade Homsi and Bedikian, {Agop Y.} and Papadopoulos, {Nicholas E.} and Kim, {Kevin B.} and Hwu, {Wen Jen} and Mahoney, {Sandy L.} and Patrick Hwu",
year = "2010",
month = "12",
day = "1",
doi = "10.1097/CMR.0b013e3283403ce9",
language = "English (US)",
volume = "20",
pages = "507--510",
journal = "Melanoma Research",
issn = "0960-8931",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in patients with metastatic uveal melanoma

AU - Homsi, Jade

AU - Bedikian, Agop Y.

AU - Papadopoulos, Nicholas E.

AU - Kim, Kevin B.

AU - Hwu, Wen Jen

AU - Mahoney, Sandy L.

AU - Hwu, Patrick

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Docosahexaenoic acid (DHA)-paclitaxel is a taxane with a unique pharmacokinetic profile. We investigated the safety and response rate of DHA-paclitaxel weekly in patients with metastatic uveal melanoma. Chemotherapy-naive and previously treated patients were eligible for this open-label phase II study. DHA-paclitaxel (500mg/m/week) was administered by a 1-hour intravenous infusion for five consecutive weeks in a 6-weeks cycle. Response was assessed using the Response Evaluation Criteria in Solid Tumors every 6 weeks. Twenty-two patients were enrolled. The patients' median age was 56 years (range: 33-79 years). Nine patients had a systemic therapy for metastatic disease earlier. The median number of treatment cycles was 1 (range 1-7 cycles). One chemonaive patient with liver metastases had partial response lasting for 5 months. Seven patients (32%) had stable disease with a median duration of 3 months (range: 3-7 months). The median overall survival was 9.8 months. Neutropenia (23%) and musculoskeletal pain (10%) were the most common grade 3 and grade 4 toxicities. As a single-agent therapy, DHA-paclitaxel is safe and well-tolerated in metastatic uveal melanoma patients. Its efficacy in this disease is limited with 32% of patients achieving stable disease. Further evaluation of DHA-paclitaxel in combination with other chemotherapeutic agents and/or targeted agents may improve its antitumor activity.

AB - Docosahexaenoic acid (DHA)-paclitaxel is a taxane with a unique pharmacokinetic profile. We investigated the safety and response rate of DHA-paclitaxel weekly in patients with metastatic uveal melanoma. Chemotherapy-naive and previously treated patients were eligible for this open-label phase II study. DHA-paclitaxel (500mg/m/week) was administered by a 1-hour intravenous infusion for five consecutive weeks in a 6-weeks cycle. Response was assessed using the Response Evaluation Criteria in Solid Tumors every 6 weeks. Twenty-two patients were enrolled. The patients' median age was 56 years (range: 33-79 years). Nine patients had a systemic therapy for metastatic disease earlier. The median number of treatment cycles was 1 (range 1-7 cycles). One chemonaive patient with liver metastases had partial response lasting for 5 months. Seven patients (32%) had stable disease with a median duration of 3 months (range: 3-7 months). The median overall survival was 9.8 months. Neutropenia (23%) and musculoskeletal pain (10%) were the most common grade 3 and grade 4 toxicities. As a single-agent therapy, DHA-paclitaxel is safe and well-tolerated in metastatic uveal melanoma patients. Its efficacy in this disease is limited with 32% of patients achieving stable disease. Further evaluation of DHA-paclitaxel in combination with other chemotherapeutic agents and/or targeted agents may improve its antitumor activity.

KW - chemotherapy

KW - melanoma

KW - paclitaxel

KW - uveal

UR - http://www.scopus.com/inward/record.url?scp=78349310964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78349310964&partnerID=8YFLogxK

U2 - 10.1097/CMR.0b013e3283403ce9

DO - 10.1097/CMR.0b013e3283403ce9

M3 - Article

VL - 20

SP - 507

EP - 510

JO - Melanoma Research

JF - Melanoma Research

SN - 0960-8931

IS - 6

ER -